SCHEMBL4017635

SCHEMBL4017635

CS(=O)(=O)c1ccccc1NS(=O)(=O)c1ccc2[nH]nc(I)c2c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CCR2 P41597 2/20 0.42
▸ KMT2A Q03164 3/20 0.41
▸ POLB P06746 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ GAA P10253 1/20 0.41
▸ GFER P55789 1/20 0.41
▸ LMNA P02545 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ TP53 P04637 1/20 0.40
▸ PTGES2 Q9H7Z7 4/20 0.40
▸ MAP2K4 P45985 2/20 0.40
▸ MAP2K7 O14733 1/20 0.40
▸ NTRK1 P04629 1/20 0.38
▸ MET P08581 1/20 0.38
▸ NTRK2 Q16620 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4014544 0.87 MAPT (0.43) CCR2KMT2APOLBMEN1GAA
SCHEMBL4009012 0.86 KMT2A (0.46) CCR2KMT2APOLBMEN1GAA
SCHEMBL4008742 0.86 PTGES2 (0.45) CCR2KMT2APOLBMEN1GAA
SCHEMBL4008442 0.85 MAP2K4 (0.48) MAPTPTGES2MAP2K4MAP2K7
SCHEMBL4007219 0.83 TP53 (0.43) CCR2KMT2APOLBMEN1GAA
SCHEMBL4009500 0.82 BRAF (0.45) KMT2APOLBMEN1GAAGFER
SCHEMBL4013522 0.81 POLB (0.52) KMT2APOLBLMNAMAPTTP53
SCHEMBL4009872 0.79 CSNK2A1 (0.55) KMT2APOLBGAA
SCHEMBL4006558 0.79 CDK7 (0.50) KMT2APOLBLMNAMAPTTDP1
SCHEMBL4007743 0.79 ITK (0.46) KMT2AMEN1NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473701-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2009-01-06 — — US disclosed
CN-100369899-C Substituted indazoles with anti-cancer activity AVENTIS PHARMA SA (FR) 2008-02-20 — — CN disclosed
CN-1642922-A Substituted indazoles with anti-cancer activity AVENTIS PHARMA SA (FR) 2005-07-20 — — CN disclosed
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-03-17 — — US disclosed
US-6858638-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-02-22 — — US disclosed
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2004-06-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 CCR2 3475/4885KMT2A 1089/4885POLB 1912/4885
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 CCR2 3578/4885KMT2A 1222/4885POLB 1915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback